ArticleBMC cancer2016
Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Diagnostic accuracy of MRI-based radiomic features for EGFR mutation status in non-small cell lung cancer patients with brain metastases: a meta-analysis.Frontiers in oncology · 2024Pooled it
- CanBMJ open · 2021Pooled it
- Association between the presence of EGFR or ALK mutations and the location of primary non-small cell lung cancer, as well as metabolic activity observed onOncology letters · 2026Article
- Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer.Translational lung cancer research · 2026Article
- Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.Nuklearmedizin. Nuclear medicine · 2026Article
- The predictive value ofFrontiers in medicine · 2026Article
- Article
- Integrating ctDNA testing forAdvances in laboratory medicine · 2025Review
- Article
- From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- ExplainableJournal of cancer research and clinical oncology · 2024Article
- The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA.Heliyon · 2024Article
- Subregion-specificAmerican journal of nuclear medicine and molecular imaging · 2024Article
- Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy.Frontiers in oncology · 2024Review
- Detection of EGFR gene polymorphisms in non-small cell lung cancer Egyptian patients: a case-control study.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2023Article
- Association between cigarette smoking history, metabolic phenotypes, andJournal of thoracic disease · 2023Article
- FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma.Scientific reports · 2023Article
- The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer.Cancer medicine · 2023Article
- OptimalFrontiers in oncology · 2023Article
- Prediction of EGFR mutation status in lung adenocarcinoma based onAmerican journal of nuclear medicine and molecular imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEGFR mutation-induced cell proliferation causes changes in tumor biology and tumor metabolism, which may reflect tumor marker concentration and 18F-FDG uptake on PET/CT. Direct aspirates of primary lung tumors contain different concentrations of tumor markers than serum tumor markers, and may correlate better with EGFR mutation than serum tumor markers. The purpose of this study is to investigate an association between cytologic tumor markers and FDG uptake with EGFR mutation status in non-small cell lung cancer (NSCLC).
methodsWe prospectively collected tumor aspirates of 61 patients who underwent EGFR mutation analysis. Serum and cytologic CYFRA 21-1, CEA, and SCCA levels were measured and correlated with EGFR gene mutations. FDG PET/CT was performed on 58 patients for NSCLC staging, and SUV was correlated with EGFR mutation status.
resultsThirty (50%) patients had EGFR mutation and 57 patients had adenocarcinoma subtype. Univariate analysis showed that female gender, never smoker, high levels of cytologic CYFRA 21-1 (c-CYFRA) and lower maximum standard uptake value (SUVmax) were correlated with EGFR mutations. ROC generated cut-off values of 20.8 ng/ml for c-CYFRA and SUVmax of 9.6 showed highest sensitivity for EGFR mutation detection. Multivariate analysis revealed that female gender [hazard ratio (HR): 18.15, p = 0.025], higher levels of c-CYFRA (HR: 7.58, and lower SUVmax (HR: 0.08, p = 0.005) were predictive of harboring EGFR mutation.
conclusionsThe cytologic tumor marker c-CYFRA was positively associated with EGFR mutations in NSCLC. EGFR mutation-positive NSCLCs have relatively lower glycolysis compared with NSCLCs without EGFR mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.